Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male
hormone that leads to benign prostate growth. By blocking the conversion of testosterone to
DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus
prolonging bicalutamide's efficacy.